Rapidly Evolving Treatment Landscape for R/R Myeloma: Integrating the Latest Data to Transform Care

Learn about and explore clinical pharmacist scenarios with use of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma in this interactive 1-hour webinar discussion with experts. Speakers will describe ways for pharmacists to prevent and manage toxicities, promote adherence, and contribute to a team-based environment to improve patient care.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

Agenda is a conversation between the faculty about the topics below:

  • Current treatment pathways in relapsed/refractory multiple myeloma
  • Scenarios commonly observed at first relapse and refractory to multiple lines of treatment including counseling points, AE management, and adherence
  • Optimizing integration of newer agents into current algorithms
  • Emerging therapies

Events

Date / Time
Event Details

Faculty

Faculty
Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Faculty
Donald C. Moore, PharmD, BCPS, BCOP, DPLA

Clinical Oncology Pharmacy Manager
Department of Pharmacy
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with relapsed/refractory multiple myeloma.

Target Audience
The target audience for this activity is pharmacists who care for patients with relapsed/refractory multiple myeloma as well as other stakeholders in hematology/oncology practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recognize approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to aid the interprofessional, collaborative care team in treatment decision-making using available data and patient-related and disease-related factors
  • Develop an understanding of the mechanisms of action of and clinical trial findings with recently FDA-approved novel therapies to facilitate optimal integration into treatment algorithms/clinical pathways
  • Explore the various clinical challenges pharmacists face with the use of approved and emerging therapies in relapsed/refractory multiple myeloma, including preventing and managing toxicities, promoting patient adherence, and fostering a team-based environment to improve patient care

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-196-L01-P has been assigned to this live application-based activity (initial release date 7/7/2022). This activity is approved for 1.0 contact hour (0.10 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.